Shots:

• In a post-hoc- sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD with motor fluctuations
• The new P-III post-hoc sub-group analysis demonstrated that long-term treatment with Ongentys when used as an add-on therapy reduced "On" time with troublesome dyskinesia and increased good "On" time without troublesome dyskinesia in patients with PD with motor fluctuations
• Long term use of therapy leads to a reduction in the patient's average daily levodopa dosage requirement. Ongentys (qd- PO) is a selective and reversible COMT inhibitor and has received the US FDA’s approval as an add-on treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes
  
   ­ Ref: PRN | Image: Neurocrine